HS Pipeline Watch: Abbvie’s Lutikizumab Advances to Phase 3 in HS

Adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy showed higher response rates in Hidradenitis Suppurativa Clinical Response 50 (HiSCR) at week 16 when treated with lutikizumab (ABT-981) 300 mg every other week or 300 mg compared to patients who received placebo, according to results from a new Phase 2 study. […]

Study: DermTech’s Melanoma Test Can Rule Out the Cancer in Real-World Settings

DermTech, Inc.’s Melanoma Test (DMT) performed well in a real-world clinical setting, the Company reports. The test assesses pigmented skin lesions, moles or dark skin spots for melanoma. In particular, the PLA detects expression of the LINC00518 (LINC) and preferentially expressed antigen in melanoma (PRAME) genes using reverse transcription-polymerase chain reaction (RT-PCR). The Company introduced […]